Viatris aktuell WKN: A2QAME ISIN: US92556V1061 Kürzel: VTRS Forum: Aktien User: DonauPirat

Nein die haben nicht nur den Ausblick bestätigt, es gab auch Medikamentenseitig gute Nachrichten. Ich frage mich eher, wer bei lächerlichen 8.40 wieder abverkauft. So wurde heute der erfolgreiche Abschluss einer Phase-3-Studie für XULANE LO, ein niedrig dosiertes Verhütungspflaster, bekannt gegeben. Die Studie erreichte ihre primären und sekundären Endpunkte für Wirksamkeit und Sicherheit und könnte das Pflaster als führende Option auf dem Markt für Verhütungsmittel positionieren. Außerdem den Abschluß erfolgreicher Erprobungen und die FDA Einreichung zur Zulassung noch dieses Jahr für das neuartige Schmerzmittel MR-107A-02 auch nach Operationen für akute Schmerzen, ohne die mit Opioiden verbundenen Risiken. Ich würde aktuell weiter kein Stück hergeben. Zumal auch die Probleme in der indischen Herstellung Indore bis August gelöst sein sollen... Hier sind aktuell locker 50% Kurserholung noch dieses Jahr plus gute Dividende drin. Schöne defensive Beimischung zu einem diversifizierten Dividenden Depot. Risiko wäre ein Krieg Pakistan/Indien und ein weiterer Zollkrieg.

Aktuell 8,17€

Gekommen von 7,6€

Aktuell 8,23 €

Tageshoch 8,46 €

mehr als 10% Plus an einem Tag?! Das ist nicht Viatris. Umgekehrt wird ein Schuh draus.

Die haben doch nur den Ausblick bestätigt und dann sowas?!

8,453 EUR +12,84 %+0,962

Jetzt kannst Du doch zufrieden sein.

Kurs recht unbeeindruckt stabil bei 7,70 € - leider kein Mega-Jump um 10% wie bei Teva gestern nach dem Earningsbeat

2025 Financial Guidance Viatris is reaffirming its 2025 outlook that was previously provided on February 27, 2025, as set forth below, after adjusting the guidance ranges solely to reflect the impact of acquired IPR&D and share repurchases as applicable. The Company is not providing forward-looking guidance for U.S. GAAP net (loss) earnings or U.S. GAAP diluted (loss) earnings per share (EPS) or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance to the most directly comparable U.S. GAAP measures, U.S. GAAP net (loss) earnings or U.S. GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR&D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company's control, and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. With respect to the Estimated Ranges provided as of February 27, 2025, and May 8, 2025, U.S. GAAP net cash provided by operating activities for 2025 is estimated to be between $2.2 billion and $2.5 billion, with a midpoint of approximately $2.35 billion. With respect to the Estimated Ranges provided as of February 27, 2025, Viatris did not provide forward-looking guidance for U.S. GAAP net (loss) earnings or U.S. GAAP diluted EPS or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance. Please see "Non-GAAP Financial Measures" for additional information.

Capital Allocation The Company is reaffirming its commitment to prioritizing returning capital to shareholders in 2025 as previously stated. Year-to-date, the Company returned more than $450 million of capital to shareholders, including over $300 million in share repurchases and ~$143 million in dividends paid. The Company expects $500 million to $650 million in total share repurchases in 2025 and expects to be opportunistic with cash available throughout the year. From a business development perspective, the Company expects to continue to pursue regional licensing and partnership opportunities with immediate revenue contribution that leverage its unique commercial and R&D infrastructure and capabilities.

Additional Highlights The Company received positive results from the Phase 3 open-label, long-term extension study for EFFEXOR® required for approval in Japan and the Company filed applications to the Ministry of Health, Labor and Welfare for approval of EFFEXOR SR Capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor to treat adults with generalized anxiety disorder, an indication for which no other treatment option is currently approved in Japan. The Company announced positive top-line results from two pivotal Phase 3 studies of its novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery and one following bunionectomy surgery. In both Phase 3 studies, all primary and secondary endpoints were met and MR-107A-02 demonstrated statistically significant and clinically meaningful results. The Company is targeting to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2025. The Company announced positive results of its Phase 3 study evaluating the contraceptive efficacy and safety of investigational XULANE LO™ low dose weekly dermal patch with 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. In this study, XULANE LO demonstrated a favorable efficacy and safety profile with no new safety concerns identified, as well as a potential best-in-class patch performance profile. The Company plans to submit an NDA to the FDA in the second half of 2025.

Quarterly Financial Highlights First quarter 2025 total revenues were $3.3 billion, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis compared to first quarter 2024, primarily driven by the negative Indore Impact. Excluding the Indore Impact, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to first quarter 2024. Brands net sales reflect the expansion of the Company's portfolio in Emerging Markets, and strong growth in Greater China and Developed Markets. Generics net sales reflect the expected negative Indore Impact, partially offset by growth in certain complex products in North America, strong performance across key European markets, and volume growth in JANZ. The Company generated approximately $67 million in new product revenues in the quarter and continues to expect to deliver approximately $450 million to $550 million in new product revenues in 2025. First quarter 2025 U.S. GAAP net loss was $(3.0) billion compared to U.S. GAAP net earnings of $114 million in the first quarter of 2024, and U.S. GAAP diluted EPS was a loss of $(2.55) per share in Q1 2025 compared to a gain of $0.09 per share in Q1 2024, in each case primarily driven by a non-cash goodwill impairment charge of $2.9 billion in the current quarter. See "Goodwill Impairment" for more information. First quarter 2025 adjusted EBITDA was $923 million, down 23% on a reported basis and down 12% on a divestiture-adjusted operational basis compared to the first quarter of 2024, and adjusted EPS was $0.50 per share in Q1 2025, down 25% on a reported basis and down 14% on a divestiture-adjusted operational basis compared to Q1 2024, both primarily driven by the negative Indore Impact. The Company generated U.S. GAAP net cash provided by operating activities of $535 million, and free cash flow of $493 million, including $43 million in transaction-related costs.

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook A) Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business B) Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts C) Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities

Heute gibts die Quartalszahlen! Teva hat gestern abgeräumt. Was hat Viatris in den Karten?